March 4), according to the CDE official website, Lundbeck’s clinical trial application for Class 1 chemical drug Lu AF28996 capsules has been accepted. Currently, the drug is undergoing Phase I clinical trials overseas. Parkinson’s disease is a neurological dysfunction disease with complex symptoms and difficult early diagnosis. It is common in middle-aged and elderly people. At present, the main treatment for Parkinson’s disease is drug therapy, with the purpose of reducing symptoms, delaying the progression, and improving the patient’s quality of life. Lu AF28996 is a dopamine D1/D2 receptor agonist developed by Lundbeck Pharmaceuticals. It is a relatively new anti-Parkinson therapy and is currently undergoing Phase I clinical trials overseas. Among them, a study to evaluate the safety, tolerability, etc. of Lu AF28996 in Parkinson’s patients is expected to be completed in 2025. This time, the approval of Lu AF28996’s clinical trial application in China is expected to bring a ...
Pedaling on a stationary bicycle built for two may improve the health and well-being for both people with Parkinson’s disease and their care partners, according to a small, preliminary study released today, February 29, 2024, that will be presented at the American Academy of Neurology’s 76th Annual Meeting taking place April 13–18, 2024, in person in Denver and online. Jennifer Trilk, PhD, University of South Carolina School of Medicine in Greenville, said, “Our study found that a unique cycling program that pairs people with Parkinson’s disease with their care partners can improve the physical, emotional and mental well-being of both cyclists to improve their quality of life. It is just as important that care partners also receive care, so that is why we included them as the cycling partner. The goal of our small study was to determine if tandem cycling was beneficial. The next step will be to confirm ...
Don Tracy, Associate Editor Early-stage trial results indicate that NLRP3 inflammasome inhibitors were able to achieve nearly the same weight loss as Wegovy while also reducing inflammatory biomarkers linked to heart disease. Results from an early-stage study found that a novel therapy for Parkinson disease produced nearly the same weight loss effect as the blockbuster GLP-1 receptor agonist Wegovy (semaglutide), while also lowering inflammatory biomarkers associated with heart disease. In a study published by The Journal of Pharmacology and Experimental Therapeutics, researchers for NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, aimed to discover the efficacy of the investigational NLRP3 inflammasome inhibitors NT-0249 and NT-0796 in reversing obesity-related complications. They focused on systemic inflammation and astrogliosis in the hypothalamus. To find a sufficient answer, the study relied on diet-induced obesity (DIO) mouse models treated with NT-0249 and NT-0796 to assess their impact on obesity reversal. ...
Coya Therapeutics is expanding its development plans to study the company’s lead combination therapy COYA-302 in frontotemporal dementia and Parkinson’s disease in addition to amyotrophic lateral sclerosis (ALS) This follows the announcement of successful pre-IND and Type C meetings between Coya and the US Food and Drug Administration (FDA) earlier this month about the candidate. The company plans to file an IND for developing the drug in frontotemporal dementia in Q2 2024 and start a Phase II study the same quarter. The plans for studying COYA-302 in Parkinson’s will follow later, with an IND filing and a Phase I/II start proposed in 2025. In a deal worth up to $677.25m, Dr Reddy’s Laboratories had signed a licence agreement with Coya in December to develop and commercialise COYA 302 to treat ALS in the European Union (EU), the UK, the US and Canada. Under the terms of the agreement, Coya can ...
Researchers at the University of Wisconsin–Madison have identified a protein key to the development of a type of brain cell believed to play a role in disorders like Alzheimer’s and Parkinson’s diseases and used the discovery to grow the neurons from stem cells for the first time. The stem-cell-derived norepinephrine neurons of the type found in a part of the human brain called the locus coeruleus may enable research into many psychiatric and neurodegenerative diseases and provide a tool for developing new ways to treat them. Yunlong Tao, an investigator at Nanjing University in China who was a research professor at UW–Madison’s Waisman Center when the study was performed, and Su-Chun Zhang, a UW–Madison professor of neuroscience and neurology, published their work on the cells, which they call LC-NE neurons, today in the journal Nature Biotechnology. Norepinephrine neurons in the locus coeruleus regulate heartbeat, blood pressure, arousal, memory, attention and ...
Researchers from the French National Institute of Health and Medical Research, the French National Center for Scientific Research and the University of Bordeaux in France, along with Swiss researchers and neurosurgeons, have successfully designed and tested a spinal stimulation implant to treat Parkinson’s disease. Conducted in collaboration with the Swiss Federal Institute of Technology in Lausanne and the Lausanne university and hospital (UNIL CHUV), the implant was tested to correct disabling gait disorders, which are associated with 90% of people living with advanced Parkinson’s and are often resistant to treatment. Parkinson’s disease is a neurodegenerative condition which progressively damages and leads to a loss of nerve cells in parts of the brain. Gait disorders are commonly caused by weakness of the hip and lower extremity muscles, such as cerebral palsy, muscular dystrophy and spinal muscular dystrophy. The implant directly stimulates nerve cells in the spinal cord responsible for controlling leg ...
The report outlines ways the government can help patients with Parkinson’s disease Parkinson’s UK has called on the government to take action to help people with Parkinson’s disease (PD) get their medication on time in hospital, as part of its relaunched ‘Get It On Time’ campaign to mark World Patient Safety Day on 17 September. The charity, alongside Diabetes UK, Epilepsy Action, National Aids, Rethink Mental Illness and the Richmond Group, supported by the Royal College of Emergency Medicine and the Royal Pharmaceutical Society, outlined in a joint statement how the government can take action to help patients with PD. PD is a progressive neurological condition which affects an estimated 128,000 people in England. People living with PD can experience severe harm to their health, such as trauma, as a result of not receiving their medication on time while in hospital. The issue also affects patients living with diabetes, epilepsy ...
An international survey conducted by Parkinson’s Europe, developed in partnership with STADA, has revealed that people taking oral medications for Parkinson’s disease experience varying effects. The survey, financially supported by STADA’s affiliate Brittania Pharmaceuticals, involved 992 participants with advanced Parkinson’s across 53 countries. It revealed that more than 96% of respondents said that they took medication for their condition, two-thirds of which were receiving oral levodopa or another single oral therapy. Parkinson’s disease is a neurodegenerative disease that progressively damages parts of the brain. Symptoms of advanced Parkinson’s are more complex and have a stronger effect on day-to-day life. The study revealed that 65% of respondents reported varying effects; 42% reported a partial response without the usual resolution of motor symptoms; 40% reported a delayed onset of effect; and 60% reported that they ‘regularly’ or ‘often’ experienced the effect of a medication wearing off before the next dose. It also ...
Bayer and BlueRock Therapeutics have announced positive results from their phase 1 stem cell clinical trial, showing that the treatment improved symptoms of Parkinson’s disease. The trial results were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark. Parkinson’s disease is the fastest-growing neurodegenerative disease in the world and causes parts of the brain to become progressively damaged over many years. The condition affects around 145,000 people in the UK. As part of the trial, a total of 12 people with Parkinson’s underwent surgery to receive either a high or low dose of bemdaneprocel (BRT-DA01), an experimental therapy involving dopamine-producing cells developed from stem cells. Stem cells develop different types of specialised cells, including skin, muscle or brain cells. For years, researchers have been working to find a way to convert stem cells into dopamine-producing brain cells to be used to replace those that are ...
New research published in the journal Gut suggests that certain gastrointestinal symptoms could be an early warning sign of Parkinson’s disease. Symptoms including constipation, dysphagia (difficulty swallowing) and irritable bowel syndrome (IBS) are suspected to drive the development of Parkinson’s disease, along with cerebrovascular disease (CD), such as a stroke or brain aneurysm, and Alzheimer’s disease (AD). Parkinson’s is one of the fastest-growing neurodegenerative diseases in the world and affects around 145,000 people in the UK. There is currently no cure for the condition. Researchers analysed the US medical records of 24,624 people with Parkinson’s and compared them to 19,046 people with AD, 23,942 with CD, and 24,624 with healthy brains to determine whether patients with Parkinson’s experienced gut issues six years prior to diagnosis and whether they had a higher chance of developing the condition. The gastrointestinal tract possesses millions of nerve cells that communicate with the brain. Researchers ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.